Apps may quietly track your driving and raise your car insurance rates
They have nothing to do with insurance or even driving.
But Action 9 investigator Jason Stoogenke says they could cause your car insurance to go up.
Larry Johnson was shopping for car insurance which should have been a breeze since he had no wrecks and a credit score on the way up.
How to save money at the pump
'The quotes I [were] getting just didn't make sense to me,' he said.
Johnson's been a big fan of the Life360 app.
'We have kids that are driving that go to school, so we want to keep up where everybody is,' he said.
He now knows the app was keeping track of something else: His family's driving.
'It's shocking and it feels, you know, like a violation almost,' he said.
Johnson deleted Life360 and plenty of other apps on his phone.
"I look for location. I look for tracking data, and I look to see what they do with that data and if I can opt out or not. And if I can't, then I don't use the app,' he said.
The Texas Attorney General is taking legal action, claiming a data broker, called Arity, embedded tracking technology in popular apps without telling consumers, including Life360. The lawsuit alleges, 'When a consumer downloaded the third-party app onto their phone, they also unwittingly downloaded defendants' software.'
It goes on to say, 'Defendants could monitor the consumer's location and movement in real-time.'
EPIC privacy analyst Sarah Geoghegan says confusing and lengthy terms and conditions shouldn't give companies free reign with your information.
'We have no way of knowing how this is going to be used against us,' she said. 'You're opting into an app that is supposed to be about family safety. You don't understand that that means through many, like down the ecosystem, down the data chain, that that actually is your car insurance company.'
You've probably never heard of Arity, but you've probably heard of its owner, Allstate.
Allstate doesn't just use the data, itself. The company also sells it to other insurance companies.
Allstate shared a screenshot with Channel 9's sister station in Atlanta, WSB. It says you can opt in to share your data to possibly get a better rate.
But the Texas Attorney General lawsuit alleges companies are collecting and selling information on drivers who never opt in that way.
When WSB reached out to Arity, they pointed WSB back to the Attorney General lawsuit.
It includes an exhibit showing consumers to allow location and motion data to be shared when they sign up for Life360.
And in their legal response, Arity claims, 'The Arity Companies are separate and distinct legal entities from The Allstate Corporation and its insurance company affiliates.'
But when WSB reached out to Arity regarding this news report, an Allstate representative with an Allstate email responded, saying, 'Consumers who choose to share driving data through Arity-powered apps can access emergency assistance, track fuel efficiency and unlock personalized insurance rates after a clear notice and explicit opt-in process.'
And how good even is that data?
Tina Marie Johnson's case signed up for an actual driving app through her auto insurance, not Life360.
'Last year alone, my rates went up three times. And I have no accidents, no speeding tickets, no nothing,' she said.
Johnson says the app regularly dinged her for unsafe driving for her car's automatic braking. Then there was the time she says she was using a scooter inside a grocery store.
"It was reading me drive and I'm like, 'Wait a minute. What's going on here?'" she said.
Federal lawmakers recently introduced a bill -- the Delete Act -- that would allow consumers to ask data brokers to delete this information and even allow you to join a 'Do Not Track' list. It's in committee. It's unclear how likely it is to pass.
VIDEO: Federal lawmakers outline plan to expand digital privacy nationwide

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Human Osteoblasts Market to Reach US$ 87.1 Million by 2033
The market is currently experiencing robust growth, fueled by a post-pandemic surge in orthopedic surgeries and significant investment in regenerative medicine. Innovations in 3D bioprinting and smart scaffolds are creating new therapeutic possibilities for bone repair. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global human osteoblasts market was valued at US$ 48.2 million in 2024 and is expected to reach US$ 87.1 million by 2033 at a CAGR of 6.8% during the forecast period 2025–2033. The future potential of the human osteoblasts market lies in the convergence of artificial intelligence with advanced biomanufacturing. AI-powered platforms are now capable of analyzing genomic data from 1000s of individuals to predict osteoblast response to new drug compounds, drastically reducing discovery timelines. This synergy is enabling the creation of patient-specific 3D-bioprinted bone grafts. As of 2025, researchers are successfully embedding patient-derived osteoblasts into custom scaffolds with 95% cell viability post-printing. These constructs are being tested in preclinical models for craniofacial reconstruction and spinal fusion, promising a new era of personalized regenerative medicine. Demand for highly characterized osteoblasts for these applications is projected to soar. Download Sample Pages: Another significant growth frontier of the human osteoblasts market is the application of osteoblast research to counteract microgravity-induced bone loss in astronauts. With 3 new long-duration space missions planned by international agencies before 2028, research into osteoblast function in simulated microgravity is intensifying. Furthermore, the veterinary orthopedics market represents a substantial, untapped opportunity. In 2024, an estimated 1.2 million companion animals in the U.S. alone underwent procedures for fractures or degenerative joint diseases. The development of canine and equine osteoblast cell lines for testing new veterinary implants and cell-based therapies is an emerging field that could create an entirely new vertical within the broader market. Key Findings in Human Osteoblasts Market Market Forecast (2033) US$ 87.1 million CAGR 6.8% Top Drivers Rising prevalence of osteoporosis and degenerative bone diseases globally. Technological advancements in cell-based therapies and tissue engineering. Increasing geriatric population driving demand for orthopedic surgical procedures. Top Trends Shift towards personalized medicine using patient-derived osteoblast cultures. Development of 3D bioprinting for creating patient-specific bone grafts. Growing adoption of minimally invasive bone regeneration surgical techniques. Top Challenges Expensive cell-based therapies and procedures. Stringent and complex regulatory approval pathways for new biologics. Top 12 Key Players Strategically Dominate the Evolving Global Human Osteoblasts Market The competitive environment is both concentrated and highly specialized. Analysis in 2024 consistently identifies 12 key players shaping the industry. These include Sigma-Aldrich, Athersys Inc., Cerapedics Inc., CryoLife, Inc., and Cytori Therapeutics Inc. Other notable companies are USA Stem Cell Inc., Vericel Corporation, Wright Medical Group N.V, Biocomposites, BD, Zimmer Biomet, and PromoCell. In the crucial U.S. orthopedic biomaterials sector, a key application area, 3 major competitors—Medtronic, DePuy Synthes, and Stryker—were noted as dominant forces in 2024. Suppliers offer highly specific product lines to meet diverse research needs. As of 2025, PromoCell provides 4 primary product categories related to osteoblasts, including cells and specialized growth media. Similarly, Innoprot offers 2 distinct types of primary human osteoblasts as of 2024 Human Calvarial and Human Femoral Osteoblasts in the human osteoblasts market. InSCREENex provides 1 specific immortalized human osteoblast cell line, CI-huOB. Product quality and performance are paramount. Lonza guarantees 10 population doublings for its Clonetics™ Normal Human Osteoblasts, ensuring robust expansion for 2024 research. Innoprot's immortalized cells demonstrate a growth potential of over 30+ passages, a significant advantage. Recent Product and Technology Launches Signal Rapid Advancement Within the Market Innovation remains a cornerstone of human osteoblasts market growth, with companies actively launching advanced products. On April 15, 2024, CryoLife, Inc. introduced 1 new osteoblast culture system designed to enhance cell viability. Zimmer Biomet followed suit in February 2024, launching 1 new bioreactor system for osteoblast cultivation with improved scalability. Innovation extends to cell preservation. In 2024, PromoCell released 1 new protein- and animal component-free cryopreservation medium, Cryo-SFM Plus, featuring advanced antioxidant technology. Intellectual property is also a key competitive tool. Bone Solutions Inc. was awarded 5 new patents in fiscal year 2025 for its Mg OSTEOCRETE technology, a bone substitute that stimulates osteoblast activity. Practical usability is crucial for clinical adoption. Bone Solutions' Mg OSTEOCRETE boasts a preparation time of just 30 seconds, a significant handling benefit for 2025 applications. To support adjacent research fields, PromoCell also launched 1 new Cancer Media Toolbox in 2024 to facilitate the establishment of primary cancer cell lines and complex 3D tumor models. Active Clinical Trials for Osteoblast-Related Therapies Underpin Future Market Expansion The clinical development pipeline is a strong indicator of future commercial opportunities. In February 2024, Biocomposites initiated 2 Phase 2 clinical trials for its STIMULAN VG® bone graft substitute. These trials will assess efficacy in treating diabetic foot osteomyelitis and stage 4 pressure ulcers. Osteosarcoma research, a critical area for the human osteoblasts market, is also advancing. In 2024, the Osteosarcoma Institute (OSI) sponsored 1 Phase 2 clinical trial in Spain for OMO-103, a promising MYC inhibitor. A remarkable 25 months was the fast-tracked timeline to launch the OMO-103 trial, showcasing increased efficiency in clinical development. In the United States, a 2024 study was published on 1 FDA/IRB-approved GMP-manufactured stem cell product, PSC-01, for knee osteoarthritis. The study showed that a single treatment provided pain reduction and increased function for 2.5 years. Research methodologies are also being refined. A 2024 clinical trial enrolled 30 patients to analyze the effects of lasers on alveolar bone preservation. A Phase 1 trial protocol published in 2024 detailed a 3+3 dose escalation method for a study using human umbilical cord-derived osteoblasts for femoral head osteonecrosis. Favorable Regulatory Approvals in 2024 Create a Promising Outlook for Therapies The regulatory climate for cell and gene therapies in the human osteoblasts market became increasingly favorable in 2024. The FDA approved 7 new cell and gene therapy products Amtagvi, Aucatzyl, Beqvez, Kebilidi, Ryoncil, Symvess, and Tecelra. The pace of approvals is accelerating, with 3 of these therapies gaining approval in early 2024 alone. On December 19, 2024, the FDA approved 1 mesenchymal stem cell product, Ryoncil from Mesoblast. Another landmark approval was granted on November 13, 2024, for 1 gene therapy for AADC deficiency, Kebilidi from PTC Therapeutics. On November 8, 2024, the FDA approved 1 CD19-directed T-cell immunotherapy, obecabtagene autoleucel (Aucatzyl), from Autolus Inc. The recommended dose for Aucatzyl is 410x10^6 CAR-positive viable T-cells. StemCyte received approval for 1 allogeneic hematopoietic stem cell therapy, Regenecyte, on November 26, 2024. Patent activity, a precursor to commercialization, is also strong. Innovators at the University of Pittsburgh were issued 5 patents in August 2024, while University of Minnesota researchers secured 111 US patents in 2024 for various health science discoveries. Significant Funding and Strategic Grants Accelerate Osteoblast-Focused Research and Development Robust financial investment is fueling the engine of scientific discovery across the global human osteoblasts market. The Osteosarcoma Institute (OSI) awarded $1,100,000 to 3 groundbreaking osteosarcoma research projects during its 2023–2024 grant cycle. One of these grants provided $500,000 in funding to Dr. David Lyden's team for a project focused on metastasis. The impact of such funding is often magnified. Building on an initial OSI grant, Baylor College of Medicine secured $4,500,000 in additional funding in 2024 to advance CAR-T therapy research. International collaborations are also being funded. In October 2024, one US–Israel Binational Science Foundation grant was awarded to a team including University of Vermont Cancer Center members to study osteosarcoma epigenetics. Wherein, government funding remains critical. In August 2024, Medical College of Georgia scientists received a five-year grant of $2,400,000 from the National Institute on Aging to study how stress hormones signal the skeleton. Philanthropic efforts are also significant, with over $4,600,000 raised from more than 1,000 donations in 2024 to support the OSI's vital mission. Diverse and Critical Applications Are Driving Widespread Adoption Across Multiple Fields The utility of human osteoblasts market extends across a wide spectrum of research and clinical applications. The dynamic interplay between 2 key cell types, osteoblasts and osteoclasts, is central to bone health, driving research into osteoporosis. In the laboratory, standardized protocols are essential. Human osteoblasts from PromoCell require approximately 3 weeks to show detectable mineralization in culture. Advanced 3D modeling is becoming a standard research tool. InSCREENex's immortalized human osteoblasts can form 3D "mini-bones" when cultured under specific conditions. Suppliers like PromoCell target 3 key application areas cell expansion, culture initiation, and differentiation. A 2024 study highlighted the use of 1 new 3D model based on human fetal osteoblasts to study osteocyte commitment. The clinical relevance is clear. The classic period for new bone formation after a tooth extraction, a process driven by osteoblasts, is 6-10 weeks. A 2025 study analyzed ion release from 3D printed scaffolds at 3 days, 7 days, and 15 days, key time points for osteoblast interaction. Quality Guarantees and Emerging Technologies Redefine the Global Human Osteoblasts Market The reliability of research outcomes depends on the quality of the underlying cell products. Suppliers in the market provide stringent quality guarantees. PromoCell guarantees >500,000 viable cells per cryovial after thawing. Innoprot similarly ensures >500,000 viable cells in each vial, cryopreserved at passage one, while Lonza guarantees ≥500,000 viable cells per ampule. For immortalized lines, Innoprot provides >1,000,000 viable cells per vial, and InSCREENex includes >0.5 million viable cells per vial. Longevity in culture is also specified. Innoprot guarantees 15 population doublings for its primary osteoblasts post-delivery. PromoCell recommends a split ratio of 1:3 to 1:6 for its primary cells. To support targeted research, PromoCell holds >100 HLA-typed cell donors in stock as of 2024, offering 4-digit high-resolution typing. The InSCREENex cell line was derived from a 63-year-old female donor. Concurrently, emerging technologies are creating new opportunities for the human osteoblasts market. Three key trends noted in the 2024 orthopedic biomaterials market are biodegradable materials, 3D printing, and nanotechnology. A September 2024 paper detailed 1 study using collagen-based 3D printed scaffolds to investigate osteoblast activity. A May 2024 publication described 1 new 3D in-vitro model using human fetal osteoblasts. A 2025 study utilized 2 cell lines to test 3D printed composite samples, using standards prepared from 1,000 mg/L stock solutions and a plating density of 10,000 cells/well for viability tests. Customize the Data Scope to Match Your Objectives: Strategic Alliances and Focused Regional Developments Indicate Strong Global Market Growth Corporate strategies and regional activities in 2024 and 2025 underscore a commitment to global expansion of the human osteoblasts market. On March 10, 2024, 1 major collaboration was announced between Athersys Inc. and Cerapedics Inc. to develop a novel osteoblast-based therapy. Service providers are also expanding. In 2024, Thermo Fisher launched its "Accelerator™ Drug Development" solutions, offering 360-degree support to biotech companies. Licensing agreements are expanding market access for key biologics. Bio-Thera Solutions entered into 1 exclusive licensing agreement on December 24, 2024, for its ustekinumab biosimilar. On the same day, GlycoNex announced 1 licensing agreement for its denosumab biosimilar, a therapy for bone loss. Regional market activities are intensifying. In 2024, 1 pivotal Phase 2 trial for osteosarcoma was opened in Barcelona, Spain. Stryker expanded with 1 new testing facility in India in February 2024. In May 2024, Sanofi announced 1 new partnership with OpenAI to accelerate R&D. The North American market saw the FDA grant 1 US approval to Pfizer's Beqvez on April 25, 2024. Europe showed activity with 1 approval by the UK's MHRA on January 15, 2025. The Asia-Pacific region is also growing, evidenced by 1 approval in Japan on January 7, 2025, for Biocon's ustekinumab. Global Human Osteoblasts Market Major Players: Athelas Bionova Scientific Cell Signaling Technology Corning EMD Millipore Invitrogen Lonza Merck Group NantKwest Promega R and D Systems ReproCELL Sigma-Aldrich Stemcell Technologies Thermo Fisher Scientific Other Prominent Players Key Market Segmentation: By Product Human Cell Culture Osteoblast Cell Lines By Application Traumatic Injuries Road Accidents Regeneration Surgeries Orthopedics Musculoskeletal and Spine Neurology By End user Hospitals Specialty Clinics Ambulatory Surgical Centers By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Is Lincoln Electric (LECO) Outperforming Other Industrial Products Stocks This Year?
The Industrial Products group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Lincoln Electric Holdings (LECO) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out. Lincoln Electric Holdings is a member of our Industrial Products group, which includes 189 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Lincoln Electric Holdings is currently sporting a Zacks Rank of #2 (Buy). Over the past three months, the Zacks Consensus Estimate for LECO's full-year earnings has moved 5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. According to our latest data, LECO has moved about 28.4% on a year-to-date basis. Meanwhile, the Industrial Products sector has returned an average of 6.7% on a year-to-date basis. As we can see, Lincoln Electric Holdings is performing better than its sector in the calendar year. Life360 (LIF) is another Industrial Products stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 107.4%. Over the past three months, Life360's consensus EPS estimate for the current year has increased 20.8%. The stock currently has a Zacks Rank #2 (Buy). To break things down more, Lincoln Electric Holdings belongs to the Manufacturing - Tools & Related Products industry, a group that includes 8 individual companies and currently sits at #223 in the Zacks Industry Rank. On average, stocks in this group have gained 13.2% this year, meaning that LECO is performing better in terms of year-to-date returns. In contrast, Life360 falls under the Security and Safety Services industry. Currently, this industry has 16 stocks and is ranked #44. Since the beginning of the year, the industry has moved +19.5%. Investors with an interest in Industrial Products stocks should continue to track Lincoln Electric Holdings and Life360. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lincoln Electric Holdings, Inc. (LECO) : Free Stock Analysis Report Life360, Inc. (LIF) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
an hour ago
- Yahoo
Chinatown acid attack suspect Marquis Johnson charged with assault
Prosecutors charged Marquis Johnson with first-degree assault in the Aug. 8 Chinatown acid attack on a 30-year-old cook, who sustained severe injuries. The 34-year-old was charged at 4 :35 p.m. Tuesday, just under the wire of the 48-hour charging deadline. Had they not met the deadline, police would have had to release Johnson. Johnson's bail was set at $500, 000. First-degree assault is a Class B felony, punishable by up to 10 years in prison and a $25, 000 fine. Johnson likely will make his initial court appearance in Honolulu District Court this morning. Johnson surrendered at the main police station at 5 :35 p.m. Sunday after police named him Thursday and provided a photograph to the public, naming him as the Aug. 8 acid attack suspect. Johnson's arrest shocked friends, who described him as a kind, sweet person who danced ballet and flamenco. They had hoped it was a case of mistaken identity, which had occurred before. Johnson was wrongly arrested in 2022 while he was walking along a Waikiki street around midnight on Aug. 22, 2020, where two car theft suspects, who also were Black men, had been in the area. In the complaint, Johnson said he was told to lie prone on the ground, and handcuffed, in a case of mistaken identity, and that one officer used excessive force. The case was recently settled in federal court. In the Aug. 8 attack, police said the suspect approached the victim on the sidewalk, asked him a few questions, then suddenly threw sulfuric acid on the victim. The victim told police he did not know his assailant, police Lt. Deena Thoemmes said. The incident occurred at the corner of North Hotel and Smith streets. An employee of Lucky Belly, a restaurant at that intersection, said the victim, a cook, had come from Livestock Tavern to get some food items from Lucky Belly, which has the same owners. He said the attack occurred just outside Lucky Belly's kitchen after the cook left to return to Livestock Tavern. Police said the acid attack victim returned to his workplace, where co-workers aided him and called 911. A witness provided a description that resulted in a police sketch of a man wearing a do-rag head covering and glasses. Police said the assailant had a camera around his neck and was carrying a red or maroon water bottle. That description was initially shared with the public Aug. 13, five days after the attack. Police also provided images from surveillance video of the suspect, wearing a blue hooded shirt, walking across the street. The acid attack has similarities to two previous attacks, which were related to each other. The first was allegedly carried out by Paul Cameron in 2023 at a Mililani fitness center against a young woman he knew. Cameron also was charged in the second attack as an accomplice in attempted murder in an apparently random attack against a Chinese language teacher. The second attack was allegedly part of a murder-for-hire plot by Cameron to divert attention from him as a possible suspect in the first case. The man facing trial in the second attack is Sebastian Mahkwan, who Cameron allegedly enlisted while they were in jail.